Trial Profile
A Phase 3, Randomized, Open-label Study Of Lorlatinib (Pf-06463922) Monotherapy Versus Crizotinib Monotherapy In The First-line Treatment Of Patients With Advanced Alk-positive Non-small Cell Lung Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 12 Dec 2023
Price :
$35
*
At a glance
- Drugs Lorlatinib (Primary) ; Crizotinib
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms CROWN
- Sponsors Pfizer
- 24 Oct 2023 Results (n=72) assessing the feasibility of AI-powered intracranial response assessment and uncovered novel imaging prognosticators presented at the 48th European Society for Medical Oncology Congress
- 24 Oct 2023 Updated Post hoc results of PROs from the 36-month follow-up analysis (n=148, data cutoff: Sep 20, 2021) in Lorlatinib treated patients with and without baseline brain metastases and with or without central nervous system adverse events, presented at the 48th European Society for Medical Oncology Congress.
- 12 Sep 2023 Results comparing efficacy and safety of lorlatinib vs alectinib and brigatinib using matching adjusted indirect comparisons using patient level data from lorlatinib RCT (CROWN) to match the aggregate baseline characteristics of the comparator RCTs (alectinib: ALEX, ALESIA; brigatinib: ALTA-1L), presented at the 24th World Conference on Lung Cancer.